By Sohini Das Analysts feel that revenue and EBIDTA growth in the pharmaceutical sector would be in the range of 14-21 per cent in the fourth quarter of the 2022-23 fiscal. However, revenue growth is flat sequentially, and they see a slight dip in EBIDTA due to price control and field force addition. Domestic